A Phase I Trial to Investigate the Metabolism and Pharmacokinetics of an Open Label Single Dose of 200 mg [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers
Latest Information Update: 06 Nov 2021
At a glance
- Drugs BI 44370 (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 19 Aug 2014 New trial record